1stOncology™: Cancer Intelligence Service – Page 9900 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Cardiff Oncology to Present at H.C. Wainwright Global Life Sciences Conference

On March 3, 2021 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, reported that the Company will present at the upcoming H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021 (Press release, Cardiff Oncology, MAR 3, 2021, View Source [SID1234576002]). The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on Tuesday, March 9, 2021. The Company will also participate in one-on-one meetings with investors during the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Study Shows IP-001 to Amplify Tumoricidal and Immune Effect of Cancer Ablation Therapies

On March 3, 2021 Immunophotonics reported that A paper recently published in Cells has described how Immunophotonics’ immune-stimulating drug IP-001 was shown to be effective against metastatic tumors when combined with different forms tumor ablation (Press release, Immunophotonics, MAR 3, 2021, View Source [SID1234576001]). In this review, the authors briefly discuss the current applications of local ablation for cancer treatment and the effects of IP-001 in combination with other ablation therapies, a therapeutic approach that is pioneering the field of Interventional Immuno-Oncology (IIO).

Kineta Presenting at Multiple Investor Conferences in March 2021

On March 3, 2021 Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology and neuroscience reported that Kineta will be presenting at multiple virtual investor events in March 2021 (Press release, Kineta, MAR 3, 2021, https://kinetabio.com/2021/03/03/kineta-presents-at-conferences-march-2021/?utm_source=rss&utm_medium=rss&utm_campaign=kineta-presents-at-conferences-march-2021 [SID1234576000]). Shawn Iadonato, Kineta Chief Executive Officer and Craig Philips, President, will present an overview of the company with a focus on its novel VISTA immuno-oncology program at the following events:

Cowen 41st Annual Health Care Conference
March 1-4, 2021
Private company presentations

H.C. Wainwright Global Life Sciences Conference
March 9-10, 2021
Private company presentations

Solebury Trout Virtual Spring Private Company Showcase
March 11, 2021 11:20-11:40AM Pacific

Life Science Innovation Northwest
March 30-31, 2021

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference

On March 3, 2021 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens reported that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021 (Press release, Xenetic Biosciences, MAR 3, 2021, View Source [SID1234575999]).

In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website here.

The video webcast presentation will be available for viewing on-demand beginning Tuesday, March 9, 2021, at 7:00 AM ET for those registered for the event and will be accessible on the IR Calendar page of the Investors section of the Company’s website (xeneticbio.com).

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

On March 3, 2021 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that members of its senior management team are scheduled to participate in the following virtual investor conferences in March (Press release, CRISPR Therapeutics, MAR 3, 2021, View Source [SID1234575998]):

Barclays Global Healthcare Conference
Date: Tuesday, March 9, 2021
Time: 10:20 a.m. ET

33rd Annual Roth Conference
Date: Monday, March 15, 2021
Time: 1:30 p.m. ET

A live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company’s website at View Source A replay of the webcasts will be archived on the Company’s website for 14 days following each presentation.